Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine E Clarridge

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|December 10, 2022
Overview of FDA Drug Approval and LabelingKatherine E Clarridge, Stacy J Chin, Kelly D Stone
The Virtual Mentor : VM|December 5, 2012
Should all u.s. Physicians speak spanish?Katherine E Clarridge, Ernest A Fischer, Andrea R Quintana, et al.
Journal of Pediatric Gastroenterology and Nutrition|January 31, 2015
Value of an Additional Review for Eosinophil Quantification in Esophageal BiopsiesEmily M Stucke, Katherine E Clarridge, Margaret H Collins, et al.
The Journal of Infectious Diseases|May 23, 2020
Kinetics of Plasma HIV Rebound in the Era of Modern Antiretroviral TherapyMichael C Sneller, Erin D Huiting, Katherine E Clarridge, et al.
Plos Pathogens|January 12, 2018
Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individualsKatherine E Clarridge, Jana Blazkova, Kevin Einkauf, et al.
The Journal of Clinical Investigation|October 8, 2019
Glycan-dependent HIV-specific neutralizing antibodies bind to cells of uninfected individualsJana Blazkova, Eric W Refsland, Katherine E Clarridge, et al.
Science Translational Medicine|September 7, 2019
An open-label phase 1 clinical trial of the anti-α<sub>4</sub>β<sub>7</sub> monoclonal antibody vedolizumab in HIV-infected individualsMichael C Sneller, Katherine E Clarridge, Catherine Seamon, et al.
Science Translational Medicine|December 8, 2017
A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infectionMichael C Sneller, J Shawn Justement, Kathleen R Gittens, et al.
The New England Journal of Medicine|April 18, 2019
Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment InterruptionChang-Yi Wang, Wing-Wai Wong, Hung-Chin Tsai, et al.
The New England Journal of Medicine|December 14, 2016
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment InterruptionKatharine J Bar, Michael C Sneller, Linda J Harrison, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
The Journal of Allergy and Clinical Immunology. in Practice|December 10, 2022
Overview of FDA Drug Approval and LabelingKatherine E Clarridge, Stacy J Chin, Kelly D Stone
The Virtual Mentor : VM|December 5, 2012
Should all u.s. Physicians speak spanish?Katherine E Clarridge, Ernest A Fischer, Andrea R Quintana, et al.
Journal of Pediatric Gastroenterology and Nutrition|January 31, 2015
Value of an Additional Review for Eosinophil Quantification in Esophageal BiopsiesEmily M Stucke, Katherine E Clarridge, Margaret H Collins, et al.
The Journal of Infectious Diseases|May 23, 2020
Kinetics of Plasma HIV Rebound in the Era of Modern Antiretroviral TherapyMichael C Sneller, Erin D Huiting, Katherine E Clarridge, et al.
Plos Pathogens|January 12, 2018
Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individualsKatherine E Clarridge, Jana Blazkova, Kevin Einkauf, et al.
The Journal of Clinical Investigation|October 8, 2019
Glycan-dependent HIV-specific neutralizing antibodies bind to cells of uninfected individualsJana Blazkova, Eric W Refsland, Katherine E Clarridge, et al.
Science Translational Medicine|September 7, 2019
An open-label phase 1 clinical trial of the anti-α<sub>4</sub>β<sub>7</sub> monoclonal antibody vedolizumab in HIV-infected individualsMichael C Sneller, Katherine E Clarridge, Catherine Seamon, et al.
Science Translational Medicine|December 8, 2017
A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infectionMichael C Sneller, J Shawn Justement, Kathleen R Gittens, et al.
The New England Journal of Medicine|April 18, 2019
Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment InterruptionChang-Yi Wang, Wing-Wai Wong, Hung-Chin Tsai, et al.
The New England Journal of Medicine|December 14, 2016
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment InterruptionKatharine J Bar, Michael C Sneller, Linda J Harrison, et al.
Pageof 1